231 related articles for article (PubMed ID: 28920002)
1. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
Albu DI; Wang Z; Huang KC; Wu J; Twine N; Leacu S; Ingersoll C; Parent L; Lee W; Liu D; Wright-Michaud R; Kumar N; Kuznetsov G; Chen Q; Zheng W; Nomoto K; Woodall-Jappe M; Bao X
Oncoimmunology; 2017; 6(8):e1338239. PubMed ID: 28920002
[TBL] [Abstract][Full Text] [Related]
2. Combination of EP
Wang Y; Cui L; Georgiev P; Singh L; Zheng Y; Yu Y; Grein J; Zhang C; Muise ES; Sloman DL; Ferguson H; Yu H; Pierre CS; Dakle PJ; Pucci V; Baker J; Loboda A; Linn D; Brynczka C; Wilson D; Haines BB; Long B; Wnek R; Sadekova S; Rosenzweig M; Haidle A; Han Y; Ranganath SH
Oncoimmunology; 2021 Mar; 10(1):1896643. PubMed ID: 33796403
[TBL] [Abstract][Full Text] [Related]
3. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE
Hong DS; Parikh A; Shapiro GI; Varga A; Naing A; Meric-Bernstam F; Ataman Ö; Reyderman L; Binder TA; Ren M; Liu M; Dayal S; Siu AY; Sachdev P; Xu L; Bhagawati-Prasad V; Tchakov I; Ooi CE; Bao X; Marabelle A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554609
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer.
Lu W; Yu W; He J; Liu W; Yang J; Lin X; Zhang Y; Wang X; Jiang W; Luo J; Zhang Q; Yang H; Peng S; Yi Z; Ren S; Chen J; Siwko S; Nussinov R; Cheng F; Zhang H; Liu M
EMBO Mol Med; 2021 Jan; 13(1):e12798. PubMed ID: 33283987
[TBL] [Abstract][Full Text] [Related]
5. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
[TBL] [Abstract][Full Text] [Related]
6. Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy.
Nishibata T; Amino N; Tanaka-Kado R; Tsujimoto S; Kawashima T; Konagai S; Suzuki T; Takeuchi M
Biomed Res Int; 2023; 2023():7133726. PubMed ID: 38058393
[TBL] [Abstract][Full Text] [Related]
7. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
8. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE
Ma X; Holt D; Kundu N; Reader J; Goloubeva O; Take Y; Fulton AM
Oncoimmunology; 2013 Jan; 2(1):e22647. PubMed ID: 23482441
[TBL] [Abstract][Full Text] [Related]
9. Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets.
Tomić S; Joksimović B; Bekić M; Vasiljević M; Milanović M; Čolić M; Vučević D
Front Immunol; 2019; 10():475. PubMed ID: 30936876
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel, Selective Prostaglandin EP4 Receptor Antagonists with Efficacy in Cancer Models.
Das D; Qiao D; Liu Z; Xie L; Li Y; Wang J; Jia J; Cao Y; Hong J
ACS Med Chem Lett; 2023 Jun; 14(6):727-736. PubMed ID: 37312837
[TBL] [Abstract][Full Text] [Related]
11. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
12. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
13. NFκB-Activated COX2/PGE
Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
[TBL] [Abstract][Full Text] [Related]
14. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
15. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
[TBL] [Abstract][Full Text] [Related]
16. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.
Xu Y; Zhao W; Xu J; Li J; Hong Z; Yin Z; Wang X
Oncotarget; 2016 Feb; 7(8):8866-78. PubMed ID: 26758420
[TBL] [Abstract][Full Text] [Related]
17. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes.
Vallerie SN; Kramer F; Barnhart S; Kanter JE; Breyer RM; Andreasson KI; Bornfeldt KE
PLoS One; 2016; 11(6):e0158316. PubMed ID: 27351842
[TBL] [Abstract][Full Text] [Related]
19. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
[TBL] [Abstract][Full Text] [Related]
20. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
